To confirm SMYD3 as an oncogenic driver through activation of AKT in BC cells, we evaluated the apoptosis and cell cycle after treating IGF-1R rescued 5637-SMYD3-shRNA and T24-SMYD3-shRNA cells with a PI3K/AKT inhibitor LY294002. Here, IGF1R is linked to breast cancer.